Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 33.24
SRPT's Cash to Debt is ranked higher than
72% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. SRPT: 33.24 )
SRPT' s 10-Year Cash to Debt Range
Min: 4.43   Max: No Debt
Current: 33.24

Equity to Asset 0.84
SRPT's Equity to Asset is ranked higher than
86% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. SRPT: 0.84 )
SRPT' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.97
Current: 0.84

-0.06
0.97
F-Score: 2
Z-Score: 3.25
M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1371.21
SRPT's Operating margin (%) is ranked higher than
58% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. SRPT: -1371.21 )
SRPT' s 10-Year Operating margin (%) Range
Min: -28680.87   Max: -71.16
Current: -1371.21

-28680.87
-71.16
Net-margin (%) -1391.71
SRPT's Net-margin (%) is ranked higher than
57% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. SRPT: -1391.71 )
SRPT' s 10-Year Net-margin (%) Range
Min: -27020   Max: -4.93
Current: -1391.71

-27020
-4.93
ROE (%) -51.83
SRPT's ROE (%) is ranked higher than
68% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. SRPT: -51.83 )
SRPT' s 10-Year ROE (%) Range
Min: -309.2   Max: -16.44
Current: -51.83

-309.2
-16.44
ROA (%) -44.72
SRPT's ROA (%) is ranked higher than
66% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. SRPT: -44.72 )
SRPT' s 10-Year ROA (%) Range
Min: -184.14   Max: -4.62
Current: -44.72

-184.14
-4.62
ROC (Joel Greenblatt) (%) -452.66
SRPT's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. SRPT: -452.66 )
SRPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2075   Max: -277.71
Current: -452.66

-2075
-277.71
Revenue Growth (3Y)(%) -52.10
SRPT's Revenue Growth (3Y)(%) is ranked higher than
60% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. SRPT: -52.10 )
SRPT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -63.2   Max: 383.5
Current: -52.1

-63.2
383.5
EBITDA Growth (3Y)(%) 26.60
SRPT's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. SRPT: 26.60 )
SRPT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -36.3   Max: 43.4
Current: 26.6

-36.3
43.4
EPS Growth (3Y)(%) 213.50
SRPT's EPS Growth (3Y)(%) is ranked higher than
100% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. SRPT: 213.50 )
SRPT' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.4   Max: 213.5
Current: 213.5

-62.4
213.5
» SRPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SRPT Guru Trades in Q1 2014

Columbia Wanger 2,635,000 sh (unchged)
Columbia Wanger 2,633,000 sh (-0.08%)
Steven Cohen 641,600 sh (-9.86%)
George Soros 25,000 sh (-89.27%)
» More
Q2 2014

SRPT Guru Trades in Q2 2014

George Soros 680,000 sh (+2620.00%)
Steven Cohen 272,100 sh (unchged)
Columbia Wanger 2,633,000 sh (unchged)
» More
Q3 2014

SRPT Guru Trades in Q3 2014

Columbia Wanger 3,237,000 sh (+22.94%)
Steven Cohen 691,200 sh (unchged)
Steven Cohen 227,300 sh (-16.46%)
George Soros 325,000 sh (-52.21%)
» More
Q4 2014

SRPT Guru Trades in Q4 2014

Jim Simons 164,278 sh (New)
Steven Cohen 1,551,300 sh (+582.49%)
Steven Cohen 1,826,500 sh (+17.74%)
Columbia Wanger 3,272,400 sh (+1.09%)
Steven Cohen 275,200 sh (unchged)
Columbia Wanger 3,272,400 sh (unchged)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.27
SRPT's P/B is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. SRPT: 2.27 )
SRPT' s 10-Year P/B Range
Min: 1.61   Max: 234
Current: 2.27

1.61
234
P/S 54.28
SRPT's P/S is ranked higher than
60% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. SRPT: 54.28 )
SRPT' s 10-Year P/S Range
Min: 1.56   Max: 2244
Current: 54.28

1.56
2244
Current Ratio 6.72
SRPT's Current Ratio is ranked higher than
81% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. SRPT: 6.72 )
SRPT' s 10-Year Current Ratio Range
Min: 0.83   Max: 35.4
Current: 6.72

0.83
35.4
Quick Ratio 6.72
SRPT's Quick Ratio is ranked higher than
82% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. SRPT: 6.72 )
SRPT' s 10-Year Quick Ratio Range
Min: 0.83   Max: 35.4
Current: 6.72

0.83
35.4
Days Sales Outstanding 90.38
SRPT's Days Sales Outstanding is ranked higher than
77% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. SRPT: 90.38 )
SRPT' s 10-Year Days Sales Outstanding Range
Min: 28.22   Max: 886.65
Current: 90.38

28.22
886.65

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.44
SRPT's Price/Net Cash is ranked higher than
93% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. SRPT: 3.44 )
SRPT' s 10-Year Price/Net Cash Range
Min: 3.35   Max: 28.2
Current: 3.44

3.35
28.2
Price/Net Current Asset Value 2.79
SRPT's Price/Net Current Asset Value is ranked higher than
95% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. SRPT: 2.79 )
SRPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.98   Max: 10.81
Current: 2.79

2.98
10.81
Price/Tangible Book 2.32
SRPT's Price/Tangible Book is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. SRPT: 2.32 )
SRPT' s 10-Year Price/Tangible Book Range
Min: 2.41   Max: 474
Current: 2.32

2.41
474
Price/Median PS Value 2.14
SRPT's Price/Median PS Value is ranked higher than
73% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. SRPT: 2.14 )
SRPT' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 76.32
Current: 2.14

0.08
76.32
Earnings Yield (Greenblatt) -37.50
SRPT's Earnings Yield (Greenblatt) is ranked lower than
57% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SRPT: -37.50 )
SRPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -53.7   Max: 0
Current: -37.5

-53.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:AB3A.Germany,
Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.
» More Articles for NAS:SRPT

Headlines

Articles On GuruFocus.com
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Feb 16 2013 

More From Other Websites
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent... Mar 24 2015
Sarepta Therapeutics' 3 Biggest Risks Mar 23 2015
Amicus Up As FDA, EU Green-light Quick Drug Filings Mar 19 2015
This Upcoming Event Could Affect Sarepta Therapeutics Investors Mar 18 2015
FDA panel to discuss Ebola vaccine development in May Mar 18 2015
FDA panel to discuss Ebola vaccine development in May Mar 18 2015
Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog Mar 17 2015
SAREPTA THERAPEUTICS, INC. Financials Mar 05 2015
Should We Be Concerned For Sarepta’s Share Prices? Mar 02 2015
ZMapp Ebola Trial Starts In Liberia: Is It Too Late? Mar 01 2015
10-K for Sarepta Therapeutics, Inc. Feb 28 2015
U.S., Liberia kick off trial of Ebola drug ZMapp Feb 27 2015
Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today Feb 26 2015
Sarepta Therapeutics reports 4Q loss Feb 26 2015
Sarepta Therapeutics reports 4Q loss Feb 26 2015
SAREPTA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Feb 26 2015
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 26 2015
Q4 2014 Sarepta Therapeutics Inc Earnings Release - Before Market Open Feb 26 2015
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent... Feb 26 2015
Will Aegerion (AEGR) Miss Earnings Estimates This Season? - Analyst Blog Feb 24 2015
Medicago wins contract to develop Ebola treatments Feb 24 2015
Medicago wins contract to develop Ebola treatments Feb 24 2015
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Feb 24 2015
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Feb 24 2015
Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog Feb 23 2015
Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog Feb 23 2015
Why Muscular Dystrophy Is Biotech's Favorite Orphan Feb 19 2015
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2014 Financial Results and Corporate... Feb 19 2015
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Feb 11 2015
Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in... Jan 14 2015
Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen... Jan 14 2015
Sarepta Therapeutics to Present Company Overview at the 2015 33rd Annual J.P. Morgan Healthcare... Jan 05 2015
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Nov 24 2014
Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant... Nov 21 2014
Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients... Nov 12 2014
Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate... Nov 11 2014
Sarepta Therapeutics tops 3Q profit forecasts Nov 06 2014
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Nov 04 2014
Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on... Oct 31 2014
Sarepta tumbles on new delay for key drug Oct 27 2014
Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Oct 27 2014
Ahead of the Bell: Sarepta Therapeutics climbs Oct 17 2014
Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in... Oct 16 2014
FDA sets approval path for Prosensa muscle disorder drug Jun 03 2014
Sarepta jumps on progress for muscle disorder drug Apr 21 2014
MARKET PULSE-AMD, Cbeyond, Halliburton, Plug Power, Prosensa, Sarepta Apr 21 2014
MARKET PULSE-AMD, Halliburton, Hasbro, Prosensa, Sarepta, Shanda Apr 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK